These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The use of proteolytic enzyme inhibitor (Trasylol) in radioreceptor assay of TSH-its application to measuring thyroid stimulating immunoglobulins (TSI) in thyroid diseases.
    Author: Kishihara M, Nakao Y, Baba Y, Ohgo S, Matsukura S, Kuma K, Imura H.
    Journal: Acta Endocrinol (Copenh); 1978 May; 88(1):65-74. PubMed ID: 77120.
    Abstract:
    In order to estimate thyroid stimulating immunoglobulins (TSI) in serum, a stable, reproducible and sensitive radioreceptor assay (RRA) capable of detecting 100 micromicron of thyroid stimulating hormone (TSH) has been developed using a proteolytic enzyme inhibitor (Trasylol), partially purified human TSH and particulate fractions of human thyroid homogenate. The binding of 125-I-labelled TSH to the crude thyroid membranes was significantly increased from 2-3% to 15-20% in the presence of Trasylol (2000 KIU per tube). Further investigations suggested that Trasylol might inhibit the aggregation of 125I-labelled TSH during incubation with these membranes. With this assay system, the serum immunoglobulins from a great majority of untreated patients with Graves' disease were shown to inhibit the binding of 125I-labelled TSH to those membranes more markedly than those from control subjects. Therefore, this RRA for TSH was considered to provide a sensitive and stable method for detecting TSI.
    [Abstract] [Full Text] [Related] [New Search]